http://gizmodo.com/these-are-the-science-stories-we-ll-be-watching-in-2016-1749459257
Human trials are also set to begin with gene-editing tools. California-based Sangamo Biosciences is planning to test enzymes to correct a gene defect that causes hemophilia. The study, which was just approved by the FDA, will be the first in vivo protein replacement platform for the treatment of Hemophilia B. The company, in cooperation with Biogen, will also begin trials to determine if a similar technique can be used to boost hemoglobin in people with the blood disorder, beta thalassaemia.
No comments:
Post a Comment